Five patients with SOX9 mutant, RAS/RAF WT CRC received anti-EGFR therapy (cetuximab or panitumumab) in combination with other treatment modalities (FOLFIRI, irinotecan). This evidence concerns the gene EGFR and colorectal carcinoma.